Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.
Basch E, Dueck AC, Rogak LJ, Minasian LM, Kelly WK, O'Mara AM, Denicoff AM, Seisler D, Atherton PJ, Paskett E, Carey L, Dickler M, Heist RS, Himelstein A, Rugo HS, Sikov WM, Socinski MA, Venook AP, Weckstein DJ, Lake DE, Biggs DD, Freedman RA, Kuzma C, Kirshner JJ, Schrag D. Basch E, et al. Among authors: sikov wm. JAMA Oncol. 2017 Aug 1;3(8):1043-1050. doi: 10.1001/jamaoncol.2016.6749. JAMA Oncol. 2017. PMID: 28208174 Free PMC article. Clinical Trial.
Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803.
Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Nelson H, Whittom R, Hantel A, Thomas J, Fuchs CS; Cancer and Leukemia Group B 89803. Meyerhardt JA, et al. J Clin Oncol. 2008 Sep 1;26(25):4109-15. doi: 10.1200/JCO.2007.15.6687. J Clin Oncol. 2008. PMID: 18757324 Free PMC article. Clinical Trial.
Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.
Shapiro CL, Halabi S, Hars V, Archer L, Weckstein D, Kirshner J, Sikov W, Winer E, Burstein HJ, Hudis C, Isaacs C, Schilsky R, Paskett E. Shapiro CL, et al. Eur J Cancer. 2011 Mar;47(5):683-9. doi: 10.1016/j.ejca.2010.11.024. Epub 2011 Feb 14. Eur J Cancer. 2011. PMID: 21324674 Free PMC article. Clinical Trial.
Clinical trials in triple negative breast cancer.
Reeder-Hayes KE, Carey LA, Sikov WM. Reeder-Hayes KE, et al. Among authors: sikov wm. Breast Dis. 2010;32(1-2):123-36. doi: 10.3233/BD-2010-0310. Breast Dis. 2010. PMID: 21778571 Review.
Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303).
Romanus D, Kindler HL, Archer L, Basch E, Niedzwiecki D, Weeks J, Schrag D; Cancer and Leukemia Group B. Romanus D, et al. J Pain Symptom Manage. 2012 Feb;43(2):205-17. doi: 10.1016/j.jpainsymman.2011.09.001. Epub 2011 Nov 21. J Pain Symptom Manage. 2012. PMID: 22104618 Free PMC article. Clinical Trial.
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Sikov WM, et al. J Clin Oncol. 2015 Jan 1;33(1):13-21. doi: 10.1200/JCO.2014.57.0572. Epub 2014 Aug 4. J Clin Oncol. 2015. PMID: 25092775 Free PMC article. Clinical Trial.
Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426).
Warner ET, Ballman KV, Strand C, Boughey JC, Buzdar AU, Carey LA, Sikov WM, Partridge AH. Warner ET, et al. Among authors: sikov wm. Breast Cancer Res Treat. 2016 Aug;159(1):109-18. doi: 10.1007/s10549-016-3918-5. Epub 2016 Jul 22. Breast Cancer Res Treat. 2016. PMID: 27449492 Free PMC article.
Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).
Golshan M, Cirrincione CT, Sikov WM, Carey LA, Berry DA, Overmoyer B, Henry NL, Somlo G, Port E, Burstein HJ, Hudis C, Winer E, Ollila DW; Alliance for Clinical Trials in Oncology. Golshan M, et al. Among authors: sikov wm. Breast Cancer Res Treat. 2016 Nov;160(2):297-304. doi: 10.1007/s10549-016-4006-6. Epub 2016 Oct 4. Breast Cancer Res Treat. 2016. PMID: 27704226 Free PMC article.
Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).
Ollila DW, Cirrincione CT, Berry DA, Carey LA, Sikov WM, Hudis CA, Winer EP, Golshan M. Ollila DW, et al. Among authors: sikov wm. J Am Coll Surg. 2017 Apr;224(4):688-694. doi: 10.1016/j.jamcollsurg.2016.12.036. Epub 2017 Jan 13. J Am Coll Surg. 2017. PMID: 28089784 Free PMC article.
87 results